Leonard Gomella, MD

Financial relationships

  • Attribution:
    Self
    Type of financial relationship:
    Consultant or Advisor (Oncology)
    Ineligible company:
    Lantheus
    Date added:
    Date updated:
    10/31/2023
  • Attribution:
    Self
    Type of financial relationship:
    Consultant or Advisor (Oncology)
    Ineligible company:
    Exelixis
    Date added:
    Date updated:
    10/31/2023
  • Attribution:
    Self
    Type of financial relationship:
    Intellectual Property Interest (Oncology)
    Ineligible company:
    Thomas Jefferson University
    Date added:
    Date updated:
    10/31/2023
  • Attribution:
    Self
    Type of financial relationship:
    Consultant or Advisor (Oncology)
    Ineligible company:
    Astra Zeneca
    Date added:
    Date updated:
    10/31/2023
  • Attribution:
    Self
    Type of financial relationship:
    Consultant or Advisor (Specialty Not Specified)
    Ineligible company:
    Merck Pharmaceuticals
    Date added:
    Date updated:
    10/31/2023
  • Attribution:
    Self
    Type of financial relationship:
    Consultant or Advisor (Specialty Not Specified)
    Ineligible company:
    MDx Health
    Date added:
    Date updated:
    10/31/2023
  • Attribution:
    Self
    Type of financial relationship:
    Health Publishing (Specialty Not Specified)
    Ineligible company:
    Wolters Kluwer
    Date added:
    Date updated:
    10/31/2023
  • Attribution:
    Self
    Type of financial relationship:
    Health Publishing (Specialty Not Specified)
    Ineligible company:
    Canadian Journal of Urology
    Date added:
    Date updated:
    10/31/2023
  • Attribution:
    Self
    Type of financial relationship:
    Health Publishing (Specialty Not Specified)
    Ineligible company:
    Merck Manual
    Date added:
    Date updated:
    10/31/2023
  • Attribution:
    Self
    Type of financial relationship:
    Health Publishing (Specialty Not Specified)
    Ineligible company:
    McGraw Hill
    Date added:
    Date updated:
    10/31/2023
Return to Live from AUA2022: Highlights in Advanced Prostate Cancer